- Carl Zeiss Meditec’s first-quarter revenue surpassed expectations.
- Total revenue for the quarter was €490.5 million, which exceeded the estimate of €481.6 million.
- Ophthalmic Devices segment earned €376.2 million during the quarter.
- The Microsurgery segment generated €114.3 million in revenue.
- Investor recommendations for Carl Zeiss Meditec include 9 buys, 10 holds, and 1 sell.
“`
A look at Carl Zeiss Meditec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Carl Zeiss Meditec AG, a global leader in medical technology for ophthalmology, maintains a solid overall outlook based on the Smartkarma Smart Scores. With consistent scores across Value, Dividend, Growth, Resilience, and Momentum, the company appears to be well-positioned for long-term success. While the Momentum score lags slightly behind the others, the balanced ratings across key factors indicate stability and growth potential.
Offering a comprehensive range of screening, diagnostic, and therapeutic systems for various vision disorders, Carl Zeiss Meditec is a trusted provider in the industry. Operating on a global scale with a presence in key markets such as the USA and Japan, the company is strategically positioned to capitalize on opportunities for expansion and innovation in the dynamic field of medical technology.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
